表紙
市場調查報告書

癌症分子診斷的全球市場 - 策略,趨勢,預測:2020年∼2024年 (包含新冠狀病毒感染疾病大流行造成的景氣衰退預測)

Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2020 to 2024

出版商 Howe Sound Research 商品編碼 932339
出版日期 內容資訊 英文 334 Pages
商品交期: 最快1-2個工作天內
價格
癌症分子診斷的全球市場 - 策略,趨勢,預測:2020年∼2024年 (包含新冠狀病毒感染疾病大流行造成的景氣衰退預測) Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2020 to 2024
出版日期: 2020年04月16日內容資訊: 英文 334 Pages
簡介

分子診斷 (MDx) 市場,持續成長。癌症的分子診斷,由於基因學的知識的劇增而直接受益。癌症的搭配診斷,是再形成產業的新市場區隔。

本報告提供全球癌症分子診斷市場相關調查分析,以130家公司以上為對象,提供市場策略,趨勢,預測相關的系統性資訊。

目錄

第1章 簡介和市場定義

  • 所謂分子診斷
  • 診斷的革命
  • 市場定義
  • 調查手法
  • 美國的醫療市場與臨床檢驗 - 預測

第2章 市場概要

  • 市場參與企業
  • 市場區隔
  • 產業結構

第3章 市場趨勢

  • 成長促進因素
  • 成長阻礙因素
  • 儀器與自動化
  • 診斷技術的發展

第4章 分子診斷的最近的發展

  • 最近的發展
  • 新冠狀病毒的大流行削減歐洲的癌症研究
  • Veracyte的Prosigna ID患者
  • CRISPR和奈米孔洞定序的組合
  • 液態切片
  • Roche,Illumina
  • Saga,Sevier等

第5章 主要分子診斷 (MDx) 企業的簡介

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex等
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack等

第6章 全球癌症MDx市場

  • 癌症MDx - 全球市場概要:各國

第7章 全球癌症MDx市場:癌症的各類型

  • 全球市場:癌症的各類型 - 概要
  • 乳癌MDx
  • 大腸癌症MDx
  • 子宮頸癌症MDx
  • 肺癌症MDx
  • 前癌症狀態MDx
  • 黑色素瘤MDx
  • 血液MDx
  • 搭配診斷MDx
  • 其他癌症MDx

第8章 癌症治療和臨床實驗

  • FDA的抗癌劑核准
  • 2010年∼2016年開始的臨床實驗
  • 癌症治療的盛行率 - 2015年

附錄

目錄

OVERVIEW:

A market that just keeps on growing. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge. Learn all about it in this new report from Howe Sound Research. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.

Trends like ......

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. Our latest numbers factor in the different COVID forces and their timing. And their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

" Molecular Diagnostics for Cancer. Markets, Strategies and Trends. Forecasts by Cancer Type, including companion Dx and by Country. With Executive and Consultant Guides and COVID pandemic recession forecast revisions. 2020 to 2024" provides data that analysts and planners can use.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID Driven Recession

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. What is Molecular Diagnostics
  • 1.2. The Diagnostics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. Methodology
    • 1.4.1. Authors
    • 1.4.2. Sources
  • 1.5. U.S. Medical Market and laboratory Testing - Perspective
    • 1.5.1. U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

  • 2.1. Market Participants
    • 2.1.1. Academic Research Lab
    • 2.1.2. Diagnostic Test Developer
    • 2.1.3. Genomic Instrumentation Supplier
    • 2.1.4. Pharmaceutical/Reagent Supplier
    • 2.1.5. Independent Testing Lab
    • 2.1.6. Public National/regional lab
    • 2.1.7. Hospital lab
    • 2.1.8. Physician Lab
    • 2.1.9. Audit Body
    • 2.1.10. Certification Body
  • 2.2. Market Segments
    • 2.2.1. Traditional Market Segmentation
    • 2.2.2. Laboratory Focus and Segmentation
  • 2.3. Industry Structure
    • 2.3.1. Hospital Testing Share
    • 2.3.2. Economies of Scale
    • 2.3.3. Physician Office Lab's
    • 2.3.4. Physician's and POCT

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. New Diagnostics Create New Markets
    • 3.1.2. New Roles for Diagnostics
    • 3.1.3. Longevity and Outcomes
    • 3.1.3. Expanding the Pharmaceutical Toolbox
    • 3.1.4. Regulatory Retreat
  • 3.2. Factors Limiting Growth
    • 3.2.1. Falling Prices
    • 3.2.2. Lower Costs
    • 3.2.3. Testing as a Controllable Cost
    • 3.2.4. Wellness has a Downside
  • 3.3. Instrumentation and Automation
    • 3.3.1. Instruments Key to Market Share
    • 3.3.2. Bioinformatics Plays a Role
  • 3.4. Diagnostic Technology Development
    • 3.4.1. Next Generation Sequencing
    • 3.4.2. Shifting Role of Diagnostics
    • 3.4.3. Multiplexing and Foundation One
    • 3.4.4. Pharmacogenomics Technology
    • 3.4.5. Whole Genome Sequencing
    • 3.4.6. Gene Editing and Gene Therapy

4. Molecular Diagnostics Recent Developments

  • Recent Developments - Importance and How to Use This Section
  • Importance of These Developments
  • How to Use This Section
  • Coronavirus Pandemic Bites into European Cancer Research
  • Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
  • Combining CRISPR and Nanopore Sequencing
  • Liquid Biopsy Detects Cancer Early via Cell Clusters
  • Roche, Illumina unveil 15-year cancer diagnostic tie-up
  • Saga, Servier Sign Liquid Biopsy Services Deal
  • Home urine test could revolutionize diagnosis of prostate cancer
  • Cancer Gene Tests Cost-Effective for Breast Cancer Patients
  • Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay
  • OncoCyte to Buy Cancer Testing Company Razor Genomics
  • Blood Test May Eliminate Need for Exploratory Surgery
  • NGS Cancer Panel Receives New York State Conditional Approval
  • Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb
  • Icon Acquires MolecularMD
  • Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
  • Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune
  • Profiling Business
  • Illumina to Launch New NovaSeq Chip, iSeq Kit; Grow Oncology and Reproductive Health
  • Business
  • UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
  • Guardant Health, Core Diagnostics to Offer Liquid Biopsy in India
  • Invitae Q3 Revenues More Than Double
  • Illumina to Acquire Pacific Biosciences
  • Lung Cancer Panel From PlexBio Receives CE Mark

5. Profiles of Key MDx Companies

  • 10x Genomics, Inc.
  • Abbott Diagnostics
  • AccuraGen Inc
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

6. The Global Market for MDx Cancer

  • 6.1. MDx Cancer - Global Market Overview by Country
    • 6.1.1. Table - Global Market by Country
    • 6.1.2. Chart - Global Market by Country

7. Global MDx Cancer Markets - By Type of Cancer

  • 7.1. Global Market by Cancer Type - Overview
    • 7.1.1. Table - Global Market by Cancer Type
    • 7.1.2. Chart - Global Market by Cancer Type - Base/Final Comparison
    • 7.1.3. Chart - Global Market by Cancer Type - Base Year
    • 7.1.4. Chart - Global Market by Cancer Type -Final Year
    • 7.1.5. Chart - Global Market by Cancer Type - Share by Year
  • 7.2. MDx Breast Cancer
    • 7.2.1. Table Breast Cancer Testing - by Country
    • 7.2.2. Chart - Breast Cancer Testing Growth
  • 7.3. MDx Colorectal Cancer
    • 7.3.1. Table Colorectal Cancer Testing - by Country
    • 7.3.2. Chart - Colorectal Cancer Testing Growth
  • 7.4. MDx Cervical Cancer
    • 7.4.1. Table Cervical Cancer Testing - by Country
    • 7.4.2. Chart - Cervical Cancer Testing Growth
  • 7.5. MDx Lung Cancer
    • 7.5.1. Table Lung Cancer Testing - by Country
    • 7.5.2. Chart - Lung Cancer Testing Growth
  • 7.6. MDx Precancer
    • 7.2.1. Table Prostate Testing - by Country
    • 7.6.2. Chart - Prostate Testing Growth
  • 7.7. MDx Melanoma Cancer
    • 7.7.1. Table Melanoma Cancer Testing - by Country
    • 7.7.2. Chart - Melanoma Cancer Testing Growth
  • 7.8. MDx Blood
    • 7.8.1. Table Blood Testing - by Country
    • 7.8.2. Chart - Blood Testing Growth
  • 7.9. MDx Companion Dx Development
    • 7.9.1. Table Companion Dx Development - by Country
    • 7.9.2. Chart - Companion Dx Development Growth
  • 7.10. MDx Other Cancer
    • 7.10.1. Table Other Cancer Testing - by Country
    • 7.10.2. Chart - Other Cancer Testing Growth

8. Cancer Treatment and Trials

  • 8.1. FDA Cancer Drug Approvals by
  • 8.2. Clinical Trials Started 2010 to 2016
  • 8.3. Prevalence of Cancer Treatments - 2015

Appendices

  • I. United States Medicare System: January 2020 Clinical Laboratory Fees Schedule
  • II. FDA Approved Human Genetic Tests
  • III. FDA Approved Microbial Tests
  • III. FDA Approved Pharmacogenomics Tests

Table of Tables

  • Table 1: Lab Spending 2014 to 2024
  • Table 2: Market Players by Type
  • Table 3: Clinical Laboratory Departments and Segments
  • Table 4: Laboratory Management Focus - Different Approaches
  • Table 5: Key Segmentation Variables Going Forward
  • Table 6: Five Factors Driving Growth
  • Table 7: Four Factors Limiting Growth
  • Table 8: Key Diagnostic Laboratory Technology Trends
  • Table 9: Next Generation Sequencing Technologies - Speed and Cost
  • Table 10: Global MDx Cancer Market by Region
  • Table 11: Global Market by Cancer Type
  • Table 12: MDx Breast Cancer by Country
  • Table 13: MDx Colorectal Cancer by Country
  • Table 14: Cervical Cancer Testing by Country
  • Table 15: Lung Cancer Testing by Country
  • Table 16: Prostate Testing by Country
  • Table 17: Melanoma Cancer Testing by Country
  • Table 18: MDx Blood by Country
  • Table 19: MDx Companion Dx Development by Country
  • Table 20: MDx Other Cancer Testing by Country
  • Table 21: 2020 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Growth in Aging Population
  • Figure 3: Death Rates from Cancer - USA
  • Figure 4: Comparing MDx Diagnostic and Traditional Testing
  • Figure 5: 2018 Global Market Density Chart
  • Figure 6: MDx Market by Cancer - Base vs. Final
  • Figure 7: Cancer Market Base Year
  • Figure 8: Cancer Market Final Year
  • Figure 9: MDx Cancer Share by Year
  • Figure 10: Breast Cancer Testing Growth
  • Figure 11: Colorectal Cancer Testing Growth
  • Figure 12: Cervical Cancer Testing Growth
  • Figure 13: Lung Cancer Testing Growth
  • Figure 14: Prostate Testing Growth
  • Figure 15: Melanoma Cancer Testing Growth
  • Figure 16: Blood Testing Growth
  • Figure 17: Companion Dx Development Growth
  • Figure 18: Other Cancer Testing Growth
  • Figure 19: FDA Cancer Drug Approvals by Year
  • Figure 20: Clinical Trials for Immunotherapy by Year
  • Figure 21: Pie Chart of Prevalence of Cancer Treatments